Gene Therapy Slashes Cholesterol for a Year After One Shot

Imagine lowering your cholesterol with one treatment instead of taking pills every day for decades. That future just moved closer to reality.

Scientists reported Friday that 15 patients who received an experimental gene-editing treatment saw their cholesterol plunge by half and stay down for a full year. The results, published in the New England Journal of Medicine, represent a major step forward in using gene therapy to prevent heart disease.

Dr. Luke Laffin, a cardiologist at the Cleveland Clinic who led the study, says the shift in thinking is profound. For preventive cardiologists used to prescribing daily medications for years, offering a one-time cure feels revolutionary.

The treatment works by editing genes to permanently change how the body processes cholesterol. Patients who received the highest dose in the trial maintained dramatically lower levels throughout the entire 12-month follow-up period.

This marks the second major breakthrough this year. Earlier in 2024, a separate clinical trial using a different gene-editing approach also showed significantly reduced bad cholesterol in 35 patients.

The Bright Side

Heart disease kills more Americans than any other condition, yet getting people to stick with treatment remains stubbornly difficult. About half of patients who start taking daily statins stop within a year.

The reasons vary widely. Some can't access regular healthcare. Others can't tolerate the side effects. Many simply don't want to take medicine every single day for the rest of their lives.

A one-and-done treatment could eliminate all those barriers at once. Patients wouldn't need to remember daily pills, manage refills, or worry about insurance coverage gaps. One visit, one treatment, one year of protection.

Both research teams emphasize these are early safety studies. The treatments remain years away from doctor's offices. But each successful trial builds the evidence that gene editing can work safely for common diseases, not just rare genetic conditions.

The gene therapy approach once seemed like science fiction. Now it's inching toward becoming standard care, one promising study at a time.

For the millions of Americans at risk for heart disease, that progress offers something invaluable: genuine hope for a simpler, more effective path to a healthier heart.